Novo Nordisk plans to test cholesterol-lowering oral solution in phase II trial

This month, Novo Nordisk has initiated a phase II trial with the firm's cholesterol-lowering PCSK9i inhibitor, according to the Danish pharmaceutical firm's Q2 report, published on Wednesday afternoon.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance for the rest of the year
For subscribers